Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Gene | ATM |
Variant | R1882* |
Impact List | nonsense |
Protein Effect | loss of function - predicted |
Gene Variant Descriptions | ATM R1882* results in a premature truncation of the Atm protein at amino acid 1882 of 3056 (UniProt.org). R1882* has not been characterized, however, due to the effects of other truncation mutations downstream of R1882 (PMID: 16603769), is predicted to lead to a loss of Atm protein function. |
Associated Drug Resistance | |
Category Variants Paths |
ATM mutant ATM inact mut ATM R1882* |
Transcript | NM_000051.4 |
gDNA | chr11:g.108304822C>T |
cDNA | c.5644C>T |
Protein | p.R1882* |
Source Database | RefSeq |
Genome Build | GRCh38/hg38 |
Transcript | gDNA | cDNA | Protein | Source Database | Genome Build |
---|---|---|---|---|---|
XM_005271562.5 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
XM_017017789.2 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
NM_001351834.2 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
XM_011542843.3 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
XM_047426976.1 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
XM_011542843.2 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
XM_011542840.3 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
XM_006718843.4 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
XM_047426975.1 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
XM_017017790.2 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
NM_000051.4 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
XM_011542840.4 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
XM_005271562.6 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
XM_006718843.5 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
NM_000051.3 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
XM_017017790.3 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
XM_017017791.1 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
NM_001351834.1 | chr11:g.108304822C>T | c.5644C>T | p.R1882* | RefSeq | GRCh38/hg38 |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ATM R1882* | gastroesophageal adenocarcinoma | predicted - sensitive | Capecitabine + Oxaliplatin | Case Reports/Case Series | Actionable | In a retrospective analysis, treatment with the combination of Xeloda (capecitabine) and Eloxatin (oxaliplatin) resulted in a partial response and a progression-free survival of 12.3 months in a patient with gastroesophageal adenocarcinoma harboring ATM R1882* (PMID: 37129948). | 37129948 |